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AAV vector-meditated expression 
of HLA-G reduces injury-induced 
corneal vascularization, immune 
cell infiltration, and fibrosis
Matthew L. Hirsch1,2, Laura M. Conatser1,2, Sara M. Smith3, Jacklyn H. Salmon3, Jerry Wu1,2, 
Nicholas E. Buglak1,2, Rich Davis2 & Brian C. Gilger3
Over 1.5 million individuals suffer from cornea vascularization due to genetic and/or environmental 
factors, compromising visual acuity and often resulting in blindness. Current treatments of corneal 
vascularization are limited in efficacy and elicit undesirable effects including, ironically, vision loss. 
To develop a safe and effective therapy for corneal vascularization, adeno-associated virus (AAV) 
gene therapy, exploiting a natural immune tolerance mechanism induced by human leukocyte 
antigen G (HLA-G), was investigated. Self-complementary AAV cassettes containing codon optimized 
HLA-G1 (transmembrane) or HLA-G5 (soluble) isoforms were validated in vitro. Then, following a 
corneal intrastromal injection, AAV vector transduction kinetics, using a chimeric AAV capsid, were 
determined in rabbits. One week following corneal trauma, a single intrastromal injection of scAAV8G9-
optHLA-G1 + G5 prevented corneal vascularization, inhibited trauma-induced T-lymphocyte infiltration 
(some of which were CD8+), and dramatically reduced myofibroblast formation compared to control 
treated eyes. Biodistribution analyses suggested AAV vectors persisted only in the trauma-induced 
corneas; however, a neutralizing antibody response to the vector capsid was observed inconsistently. 
The collective data demonstrate the clinical potential of scAAV8G9-optHLA-G to safely and effectively 
treat corneal vascularization and inhibit fibrosis while alluding to broader roles in ocular surface 
immunity and allogenic organ transplantation.
The normal cornea is considered to be an immune privileged site that has evolved tolerance to ocular surface flora 
and environmental irritants in an attempt to prevent overt ocular inflammation that can result in blindness. This 
immune suppressed status is maintained in part by the absence of blood or lymphatic vessels, as well as a lack 
of MHC class II molecules on most of the cells that form the cornea1,2. A broad range of environmental insults 
and genetic conditions manifest in the form of corneal vascularization which occurs at a remarkably high rate 
of incidence, approximately 1.4 million patients per year in the Unites States alone3. In addition to visual distur-
bances from opacities associated with corneal vascularization, the loss of immune tolerance in the vascularized 
cornea disrupts the normal immunologic privilege, which leads to increased inflammation and scarring, and is a 
leading cause of cornea transplant rejection4,5. Medical options for the treatment of cornea vascularization, such 
as anti-inflammatory drugs, demonstrates limited and/or varied success along with the potential development of 
common vision-threatening side-effects including cataracts and glaucoma. Long-term use of these treatments, 
in addition to the requirement for frequently repeated daily applications leads to poor patient compliance and 
therefore, remains to be a significant concern. Additionally, if the drug regimens fail, several surgical options for 
treating cornea vascularization are considered, however, they can also induce neovascularization.
Gene delivery approaches using adeno-associated virus (AAV) vectors are currently the leading method of 
human gene therapy and have been used in hundreds of clinical trials for over 20 different diseases (clinicaltri-
als.gov)6. In regard to AAV gene therapy for the treatment of corneal neovascularization, work nearly a decade 
ago demonstrated that subconjunctival injections of AAV serotype 2 (AAV2) vectors harboring angiostatin or 
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endostatin cDNA prior to cornea trauma, reduced neovascularization in rodents7,8. These reports provide an 
important proof of concept for using AAV gene therapy as a prophylactic for cornea vascularization. However, 
in these examples the effects were incomplete, evaluated only over a short term (2 weeks), and did not demon-
strate efficacy in the perceived clinical situation, administration following a cornea trauma. Additionally, these 
approaches overlook the complex pathogenesis of corneal diseases by addressing only one symptom, corneal 
neovascularization, while reinstating corneal immune homeostasis, hypothetically, should prevent the onset and/
or cause regression of vascularization and many of the causes there of.
The immunomodulatory and anti-inflammatory molecule, human leukocyte antigen-G (HLA-G) was origi-
nally discovered in the human placenta where it plays a role in preventing fetus rejection by the maternal immune 
system, a process termed fetal-maternal tolerance9–11. Seven different HLA-G isoforms have been described with 
the transmembrane, or exosome-associated, and soluble isoforms, HLA-G1 and HLA-G5, respectively, among the 
most studied12. Generally, the immune suppression effects of HLA-G are elicited directly, via binding of immune 
cells to HLA-G1 and the subsequent induction of apoptosis, or indirectly, by preventing vasculature formation 
and inducing endothelial cell apoptosis (perhaps the major role of HLA-G5)12. Additionally, HLA-G induces tol-
eragenic dendritic cells, upregulates T regulatory cells (including CD4+ HLA-G+), and inhibits reactive oxygen 
species production and phagocytosis by neutrophils13–16. Low levels of HLA-G are associated with a higher inci-
dence of graft versus host disease, while higher levels of HLA-G are consistent with reduced transplant rejection17. 
For instance, HLA-G delayed skin allograft rejection in a murine model18.
The purpose of this study was to engineer and validate a therapeutic, based on a natural mechanism of immune 
suppression, for the treatment of corneal vascularization following an insult. Towards this end, HLA-G cDNA was 
enhanced by codon optimization and validated in a self-complementary AAV vector context in vitro19,20. Then, 
the optimized HLA-G1 and HLA-G5 cassettes were packaged in a capsid proficient for multi-species cornea gene 
delivery21 and administered via a single intrastromal injection, 7 days following a corneal chemical burn in a rab-
bit model. In contrast to the control injected corneas, which became heavily vascularized, corneas that received 
scAAV8G9-optHLA-G demonstrated the near complete absence of vasculature over a 2-month period following 
the insult. The results also demonstrated decreased immune cell infiltration of the cornea, which included cyto-
toxic T lymphocytes, and decreased smooth muscle actin staining in the scAAV8G9-optHLA-G treated corneas. 
Biodistribution analysis following an intrastromal injection in traumatized corneas showed that, although vector 
genomes were not detected outside of the cornea, an AAV capsid neutralizing antibody response was elicited in 
approximately 50% of the cases. The collective data demonstrate the clinical potential of scAAV8G9-optHLA-G to 
eliminate vascularization of the cornea while alluding to even broader roles in fibrosis, ocular surface immunity, 
and allogenic organ transplantation.
Results
Optimized AAV HLA-G construct and in vitro expression. Initially the HLA-G1 cDNA (accession 
BC021708) was codon optimized for theoretically enhanced transgene production in human cells, as well as to 
remove unwanted alternative open reading frames (ORFs) (Fig. 1A)22. Western blot detection of plasmid-borne 
HLA-G1 from either WT or codon optimized HLA-G1 cDNA demonstrated a consistent 3-fold elevation when 
using the codon-optimized version (optHLA-G1) in human embryonic 293 cells (Fig. S1). Next, the optHLA-G1 
transmembrane domain was deleted to generate optHLA-G5 cDNA, and both optHLA-G1 and optHLA-G5 were 
cloned into a self-complementary AAV plasmid context (Fig. 1A). Western blot analysis following transfections 
of these plasmids in 293 cells generated an anticipated single band at 39 kDA for optHLA-G1 and the expected 
smaller product for optHLA-G5 (Fig. 1B). Next, the intracellular localization of HLA-G1 (transmembrane) and 
HLA-G5 (soluble and secreted) were investigated via immunocytochemistry following transfections in 293 cells. 
Immunostaining of placental JEG-3 cells demonstrated cytoplasmic, surface, and extracellular staining (Fig. 1C). 
In contrast, 293 cells transfected with optHLA-G1 demonstrated primarily surface membrane staining while 
optHLA-G5 transfected cells appear to have more staining in the cytosol and extracellular matrix (Fig. 1C). These 
collective results demonstrate that the optimized HLA-G isoforms result in efficient protein production and the 
expected cellular localization.
AAV8G9 capsid mediates efficient gene delivery to the rabbit cornea. The chimeric capsid “8G9”, 
which is the AAV8 capsid sequence engrafted with the putative AAV9 galactose receptor binding domain, was 
found superior for human cornea transduction following intrastromal injection21. To determine if AAV8G9 also 
transduces the rabbit cornea, a self-complementary (sc) JET-GFP reporter cassette was packaged in the AAV8G9 
capsid and administered to the rabbit cornea via a 50 µl intrastromal injection of 5 × 1010 viral genomes (vg)23. 
Following an intrastromal injection of balanced salt solution (BSS) or scAAV8G9-GFP, an immediate central 
corneal opacity throughout approximately 30% of the central cornea developed (Fig. 2A,B). This opacity com-
pletely resolved within 24 hours of the injection (Fig. 2A). Using live imaging, GFP fluorescence was detected in 
the central cornea, at the location of the vector injection, twenty-one days post-injection (Fig. 2C). Quantitation 
of the signal demonstrated peak GFP intensity at 28 days post-injection (Fig. 2C).
Effect of scAAV8G9-optHLA-G on corneal vascularization in vivo. A previous report using HLA-G 
protein demonstrated HLA-G5′s function, consistent with its known roles in humans, in a rabbit model24. 
Additionally, the rabbit eye is similar in structure and size to the human eye making it a popular model for ocular 
research. Given that the AAV8G9 capsid was validated for rabbit cornea transduction (Fig. 2), the optHLA-G 
plasmid constructs were used to produce preclinical scAAV8G9 vectors. To mimic a clinically relevant scenario, 
rabbits were anesthetized and corneas were injured, prior to AAV vector injections via a 5 mm central corneal 
chemical burn with NaOH. Seven days after burn injury, intrastromal injections of scAAV8G9 vectors encoding 
GFP or, due to the exact roles of HLA-G isoforms being unknown and in an effort to increase the chances of seeing 
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a therapeutic effect, optHLA-G1 + optHLA-G5 at a 1:1 ratio (optHLA-G Combo). There were no significant 
changes associated with intraocular pressure or corneal thickness by 24 hours after injection and throughout the 
experimental evaluation period (Fig. S2). Corneal vascularization began approximately 7 days after injury, with 
a significant difference in vascularization between treatment groups by day 10 post-injury (p < 0.001) (Fig. 3). 
Quantitation of the area of vascularization using ImageJ software demonstrated increased vessel in-growth at 
every experimental time point, with maximal vascularization, in corneas treated with scAAV8G9-GFP, at 56 
days post-injury. In contrast, 2 months post-injury, subjects that received scAAV8G9-optHLA-G Combo did not 
manifest any significant vessel formation, which is 10-fold less than the scAAV8G9-GFP treated eyes (p < 0.002) 
(Figs 3 and S3).
HLA-G production and immune inhibition in the injured cornea. Following 8 weeks of observa-
tion, tissues were recovered for analysis. Histology of injury induced corneas injected with scAAV8G9-GFP 
revealed changes consisting of central corneal mononuclear cellular infiltrate, vascularization into the central 
cornea, and mild to moderate amount of fibrosis (Fig. 4A). While in comparison, histological analysis of injured 
corneas that were injected with scAAV8G9-optHLA-G Combo, had minimal cellular infiltrates and no vascu-
larization (Figs 4B, S4A). In fact, the mean cumulative histology scores of post-injury corneas injected with 
scAAV8G9-HLA-G Combo were significantly lower than the mean scores for corneas injected with the GFP 
control vector (p < 0.0005) (Figs 4B, S4A).
In addition to H&E staining, immunofluorescence was used to confirm blood vessels in the central cornea 
by revealing the presence of the endothelial intercellular junction cell marker, CD31 (Fig. 5A). Immunostaining 
for CD3 confirmed that the majority of infiltrating cells in the injured corneas treated with scAAV8G9-GFP 
were positive for the CD3 surface antigen (Fig. 5B). A subset of this population also stained positive for CD8, 
demonstrating the influx of cytotoxic T cells following cornea injury (Fig. 5B). A smaller proportion of this T cell 
population proved to be CD4+, thereby demonstrating the presence of helper T cells.
Next, cornea tissue was analyzed to correlate the phenotypic outcome to vector derived transgene production 
using immunofluorescence. Similar to our reported human results21, GFP was present throughout the cornea 
of rabbits given scAAV8G9-GFP (Fig. 5C). As expected, HLA-G proteins were evident only in corneas injected 
with scAAV8G9-optHLA-G Combo, thereby correlating the therapeutic effect to HLA-G (Fig. 5C). Furthermore, 
immunofluorescence of injured corneas treated with optHLA-G Combo vectors were negative for alpha smooth 
muscle actin (αSMA) while those treated with the GFP control vector demonstrated a positive signal throughout 
the total thickness of the cornea, with the strongest effect seen in the anterior portion of the stroma and along the 
endothelium (Fig. 5D). In addition to the difference in αSMA expression, a disruption to the organization of the 
cells and/or the collagen fibrils in the scAAV8G9-GFP treated tissues was observed (Figs 5D, S4B), suggesting that 
HLA-G may play a role in preventing corneal fibrosis.
Figure 1. Characterization of scAAV8G9-optHLA-G in vitro. (A) A cartoon of the self-complementary 
scAAV8G9-optHLA-G vector cassette. (B) Confirmation of optHLA-G isoform production in 293 cells by 
Western blot. JEG-3 cells are placental cells and serve as a positive control. To concisely represent the data, 
blot images have been cropped and aligned while images of full-length blots are shown in Supplementary 
Figure 4. (C) Diaminobenzidine staining of optHLA-G isoforms, imaged at the same exposure times, following 
transfection of 293 cells with the indicated cDNAs. ITR = inverted terminal repeat.
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AAV8G9 Biodistribution following Intrastromal Injection of Traumatized Corneas. It is of 
importance for potential clinical applications to determine the biodistribution of persistent AAV vectors follow-
ing scAAV8G9 intrastromal injections. To do this, total DNA was recovered from samples of liver and two brain 
regions; the trigeminal nerve nuclei, that innervates the cornea, and the lateral geniculate nucleus that innervates 
the retina. PCR using primers to the transgenic cassette failed to detect any viral genomes outside of the cornea. 
Despite this, at the conclusion of the study, a strong scAAV8G9 capsid-specific neutralizing antibody response 
was detected in one of the rabbits that received scAAV8G9-GFP treatment and had developed extensive corneal 
vascularization, with a titer of 1/256 (Table 1). Two other rabbits demonstrated a very mild antibody response to 
the scAAV8G9 capsid, independent of the transgene or the emergence of vascularization (Table 1).
Discussion
Corneal vascularization, which affects over 1.4 million people per year in the United States alone, is elicited by 
one of two kinds of conditions, inflammation or hypoxia. Inflammation and/or hypoxia can be the result of a vari-
ety of insults including, bacterial or viral infection, autoimmune or degenerative diseases, trauma/manipulation, 
extended wear of contact lenses, and chemical burns or toxic contamination. The invasion of vessels originating 
in the limbus not only affects visual acuity or occludes vision but also disrupts corneal immune homeostasis 
resulting in secondary conditions such as, increased inflammation and scarring, and is a major component in 
development of dry eye and in corneal transplant rejection. Current modalities to treat vascularization rely on 
frequent drug administration that are only partially effective with serious vision threatening side effects. More 
invasive procedures such as argon laser photocoagulation and transection are not particularly successful and are 
Figure 2. scAAV8G9 Mediates Gene Delivery in the Rabbit Cornea. A) Vector injection of 50ul into the 
rabbit corneal stroma causes transient corneal cloudiness. B) Quantitation of the area of cornea covered by 
the injection. C) Representative in vivo images depicting intensity of GFP expression and quantitation of GFP 
intensity of the indicted injectable at the indicated time point. (p < 0.0009). P.I. = post-injection, sc = self-
complementary.
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increasingly less employed. Therefore, a single dose therapeutic capable of preventing, or inducing regression 
of vasculature, without vision threatening side effects is needed to replace the current corneal vascularization 
treatment deficits. Towards this end, AAV gene delivery of codon optimized HLA-G isoforms was employed 
post-insult in rabbit corneas. Although incompletely understood, the effects of HLA-G are multi-factorial 
and perhaps natural in the eye, as HLA-G has been hypothesized to play a role in ocular immune privilege12. 
Furthermore, its inherent function in fetal maternal immune tolerance implies that in humans, HLA-G is a “self ” 
protein, an attribute important for successful gene therapy. Following in vitro characterization and vector vali-
dation of scAAV8G9-optHLA-G (Figs 1, 2), the experimental data demonstrate, with remarkable significance, 
three important therapeutic outcomes: i) near complete inhibition of corneal vascularization when administered 
post-trauma (Figs 3, S3), ii) maintenance of immune homeostasis by prevention of immune cell infiltration of 
the cornea (Figs 4, S2), and iii) decreased myofibroblast formation in the injured cornea (Figs 4 and S4). Further 
characterization for anticipated clinical applications indicated that AAV vectors injected into the injured corneal 
stroma inconsistently elicited an antibody response to the viral capsid (Table 1). However, following intrastromal 
injection of AAV8G9 at the indicated dose, transgenic genomes were detected outside of the cornea in the tested 
tissues (data not shown). Collectively, these preclinical results using scAAV8G9-optHLA-G gene therapy may 
facilitate the development of a single dose therapeutic capable of safely treating cornea vascularization and per-
haps other ocular and non-ocular diseases.
Initially, the codon usage of HLA-G1 was altered for envisioned human applications in a manner that 
increased overall abundance, compared to WT HLA-G cDNA, and to eliminate alternative ORFs, which can elicit 
CTLs following systemic gene therapy (Fig. S1)22. Although codon optimization is inconsistently successful25,26, 
in the case of HLA-G1 the results demonstrate 3-fold increased abundance using the synthetic ORF, which could 
be due, in part, to altered post-transcriptional regulation by microRNAs targeting WT HLA-G27,28. Conceptually, 
Figure 3. scAAV8G9-optHLA-G Combo Prevents Burn-induced Cornea Vascularization. Rabbit corneas 
were centrally burned seven days prior to a cornea intrastromal injection of scAAV8G9-GFP or scAAV8G9-
optHLA-G Combo (isoforms 1 and 5 at a 1:1 ratio). (A) Representative in vivo images depicting vascularization 
alongside images of vascularization tracings of treated corneas 42 days post-injection with the indicated vectors. 
(B) Quantitation of the traced area of vascularization immediately after corneal burn (day 0), 3 days after 
injection with the indicated vectors (day 10), and the last experimental time point (day 56) (p < 0.001 at day 10 
and p < 0.002 at day 56). sc = self-complementary.
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this allows a concomitant dose decrease and, based on the available AAV vector results in humans, lower admin-
istered doses result in less vector related immune complications and better therapeutic outcomes6.
scAAV8G9-optHLA-G intrastromal injections were well tolerated with a near complete clearing of the cornea 
by 24 hours and resolution of injection-related inflammation by 3 days post-injection (Fig. 2). These injections 
resulted in widespread corneal transduction of GFP or HLA-G isoforms in normal and injured corneas of rab-
bits, a species with a cornea of similar size to human corneas (Fig. 5). Of particular note is that the injections 
resulted in approximately 30% corneal coverage following a total injection volume of 50 ul (Fig. 2A). This volume 
injected intrastromally, inconsistently elicited neutralizing antibodies to the 8G9 capsid in the serum, 2 months 
post-injection. This result may be related to subtle differences during the actual administration (i.e. depth of 
needle in the cornea) and/or perhaps to the severity of the individual corneal response to the trauma induced 
a week prior (i.e. proximity of neovascularization to the actual injection). In contrast, no AAV vector genomes 
were noted in off-target tissue (e.g., liver, brain) suggesting that either the level of peripheral virus was below the 
sensitive detection of PCR, or AAV vector transduction was nearly entirely restricted to the cornea (data not 
shown). Either way, and although not envisioned or anticipated, successful repeated AAV vector administration 
to the cornea has been reported independent of the AAV capsid vaccination29.
At the therapeutic level, when compared to scAAV8G9-GFP, corneas injected with scAAV8G9-optHLA-G 
Combo had significantly less vascularization and inflammatory cell infiltrate 2 months following corneal injury. 
Correlating to other models where HLA-G suppresses angiogenesis, T cells, NK cells, B cells, and monocyte infil-
trate, these data in the rabbit cornea support the notion that AAV HLA-G therapy provides sustained immune tol-
erance to the ocular surface. However, HLA-G’s immune suppression capability does not come without concern, 
as it has been implicated in immune evasion of both solid and liquid tumors (reviewed in12). Therefore, in regard 
to HLA-G cornea gene therapy for vascularization and other anterior eye diseases, HLA-G production should be 
Figure 4. scAAV8G9-optHLA-G Combo Prevents Cornea Burn-induced Vascularization and Immune Cell 
Infiltration. Rabbit cornea sections were acquired 60 days following the injection of indicated vectors into 
trauma induced corneas and stained with hematoxylin and eosin. (A) Representative images of processed 
sections treated with the indicated vector preparation. (B) Quantification of clinical histological exam scores of 
all H&E sections presented in (A) (p < 0.0005).
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restricted minimally by a cornea specific promoter, such as keratocan, and perhaps by engrafted miRNA targets 
that reported to enhance tissue specific production30,31. The study herein, the constitutive and ubiquitous JET 
promoter was used32. Although indirect antibody evidence suggested at some point scAAV8G9 vectors leached 
out of the cornea in about half of the treated rabbits, we did not see any tumors develop nor did we observe any 
non-ocular pathologies (Table 1).
Figure 5. scAAV8G9-optHLA-G Combo Prevents Cornea Burn-induced Vascularization and Cytotoxic T-cell 
Infiltration. Rabbit cornea sections were acquired 60 days following the injection of indicated vectors into burn 
corneas and stained for an endothelial cell marker (CD31), T cell markers, transgene abundance, and αSMA in 
the indicated treatment groups. Scale bars = (A) 10 µm, (B) 5 µm, (C) 20 µm, (D) 200 µm.
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A somewhat unexpected finding was that scAAV8G9-optHLA-G Combo inhibited αSMA expression in 
the injured region of the rabbit cornea. αSMA is the most commonly used marker of myofibroblasts, which 
are induced by injury and are central to the development of corneal opacity. Upon cornea damage, cytokines 
including transforming growth factor beta, platelet-derived growth factor and interleukin-1 induce kerat-
ocyte differentiation to myofibroblasts, which restores the structural integrity of the cornea. However, this 
process inherently results in corneal fibrosis and opacity within 4 weeks in rabbits33. The experiments herein 
depict similar results in which the initial injury induced a corneal opacity throughout the experimental dura-
tion. Although the clinical corneal opacity scores were not significantly different between GFP control and 
scAAV8G9-optHLA-G Combo groups, the absence of myofibroblast formation supported by Masson tri-
chrome staining results suggests HLA-G inhibits cornea fibrosis (Figs 5, S4). To our knowledge, this is among 
the first reports of a correlation between HLA-G and decreased fibrosis, however, in the liver of patients with 
chronic hepatitis B there was a significant correlation between HLA-G+ cells and the fibrotic area34. Whether 
HLA-G’s influence on myofibroblast formation is distinct or causally linked to the vascularization and immune 
inhibition cascade remains to be elucidated.
The results herein demonstrate the first application, to our knowledge, using AAV vectors for HLA-G gene 
therapy in any tissue, with optimism generated for a single dose safe and effective treatment for, minimally, cor-
neal vascularization. This effectiveness of HLA-G gene therapy in cornea has widespread implications for the 
treatment of ocular surface disorders in which normal immunologic tolerance is disrupted, including corneal 
injuries, infections, immune-mediated diseases, and prevention of corneal transplant rejection in both low and 
high-risk patients. Beyond the cornea, the implications of scAAV-optHLA-G for the treatment of dry eye, corneal 
scarring, neovascular glaucoma, uveitis, retinal/choroid vascularization, and theoretically, any solid organ trans-
plant have yet to be realized.
Materials and Methods
Optimized AAV HLA-G construct and in vitro expression. The HLA-G1 cDNA was codon optimized 
(GenScript USA, Piscataway, NJ) and Western blot detection was used to compare the amount of plasmid-borne 
HLA-G1 from either WT or codon optimized HLA-G1 cDNA. Using PCR amplification, the transmembrane 
domain of HLA-G1 was then deleted to generate the soluble isoform, HLA-G5, cDNA. Following transfec-
tions of these plasmids in Human embryonic kidney 293 cells, cell lysate was made and Western blot analysis 
was used to detect the size of the protein products that were generated. Immunocytochemistry, with the use of 
3,3′-Diaminobenzidine (DAB), was used to look at the intracellular localization of HLA-G1 and HLA-G5 in 
transfected 293 cells. Human placenta cells (JEG-3 cells) were used as a positive control (ATCC® HTB36™). Both 
HLA-G1 and HLA-G5 were then cloned into a self-complementary AAV plasmid context.
In vivo HLA-G expression following intrastromal injection of scAAV8G9-optHLA-G. All of 
the animals used during this study were done so in accordance with the NIH Guide for the Care and Use of 
Laboratory Animals and an approved protocol monitored by the North Carolina State University Institutional 
Animal Use and Care committee (IACUC). Normal outbred male New Zealand White rabbits (Oryctolagus cunic-
ulus) were used. While the rabbits were under anesthesia and following the application of a topical anesthetic 
(0.5% proparacaine HCL [Alcaine, Alcon Laboratories, Fort Worth, TX]), a unilateral corneal wound was created 
by incubating a 5 mm circular filter disc in 20ul of 1 M NaOH and applying it to the central cornea for 30 sec-
onds35,36. Seven days after corneal wounding, each rabbit was anesthetized and both eyes received an intrastro-
mal injection with either saline solution (balanced salt solution (BSS), Alcon Laboratories, Fort Worth, TX), or 
scAAV8G9 vectors encoding for GFP or, at a 1:1 ratio, a combination of HLA-G1 + HLA-G5 vectors (n = 3 for 
each treatment group). For each injection, a 31-gauge needle was used to deliver 50 µL of either the saline solu-
tion or, at a viral concentration of 1 × 109 vg/µl, the AAV vectors into the superficial corneal stromal. Following 
wounding and again after intrastromal injections, prophylactic antibiotics (Moxifloxacin, Alcon Laboratories, 
Fort Worth, TX) were applied topically to each cornea and buprenorphine was given subcutaneously to help 
reduce post-operative discomfort. Post injection and while conscious, in vivo expression of GFP was evaluated 
in rabbits that were injected with scAAV8G9-GFP using a scanning laser ophthalmoscope (SLO) with a 482 nm 
laser source (Infrared cSLO; RetiMap Roland Consult, Germany, Wiesbaden, Germany). The intensity of GFP 
Animal ID Serum Dilution
Saline
Rabbit-1 no Ab
scAAV8G9-GFP
Rabbit-6 1:2
Rabbit-7 No Ab
Rabbit-8 1:256
scAAV8G9-optHLA-G Combo
Rabbit-12 1:4
Rabbit-13 No Ab
Rabbit-14 No Ab
Table 1. Neutralizing Antibody Titer Following scAAV8G9 Intrastromal Injection of Burned Corneas.
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fluorescence expression was then quantitated from the in vivo images using a previously described method 
for calculating corrected total cell fluorescence (CTCF), where CTCF is equal to, Integrated Density - (Area of 
selected cell/ fluorescence X Mean fluorescence of background readings)37,38.
Effect of scAAV8G9-optHLA-G on corneal vascularization in vivo. Neovascularization was moni-
tored by slit-lamp biomicroscopy and photography, central corneal pachymetry (PachPen Handheld Pachymeter, 
Accutome, Malvern, PA), and intraocular pressure (IOP; Tonovet tonometer, Icare, Finland) were performed at 
day 0 (prior to wounding) and every 2–3 days for the following 56 days. Vascularization was quantified by con-
verting each in vivo slit-lamp biomicroscopy image files to 8-bit via ImageJ and increasing the visualization of 
vasculature with the finding edges and contrast enhancement processes, along with inverting all black and white 
values. The converted images were then opened in GNU Image Manipulation Program (GIMP 2.8.20), a trans-
parent overlay layer was added to each image file, vessels were manually traced on to the new layer, and finally, the 
area of traced vessels was converted to total pixel number using ImageJ (Fig. S3).
Expression and re-establishment of immune tolerance by HLA-G in the injured cornea. Rabbits were 
euthanized and eyes were recovered and post fixed overnight, at 4 °C, in neutral buffered formalin and then stored in 
70% EtOH until being paraffin embedded. Tissue was sectioned at 5 μM and histopathologically evaluated for the quan-
titation of cornea vasculature (CD31) and immune response looking at the expression of CD3, CD8, and CD4. Sections 
stained with hematoxylin and eosin were examined by light microscopy. The corneal histologic scoring scheme was 
modified from a previously described method39 and graded the following areas, degree of cellular infiltrate, extent of 
fibrosis, and extent of vascularization. Scores of 0–4 were assigned based on the following rubric: 0, no significant lesion; 
1, low numbers of inflammatory cells, mild fibrosis, minimal vascularization; 2, moderate, diffuse stromal inflamma-
tory cell infiltrates, fibrosis, or neovascularization; 3, moderate to marked diffuse stromal inflammatory cell infiltrate, 
fibrosis, or neovascularization; 4, marked, diffuse, cellular infiltrate, fibrosis, vascularization. Cumulative histologic 
scores were then analyzed and reported as mean ± standard deviation (SD) per treatment group.
Immunohistochemistry. Cornea tissues were embedded in paraffin and using a microtome, 5 μm sections 
were cut and then mounted and dried onto slides. In order to stain the tissue sections and use Alexa Fluor conju-
gated secondary antibodies to image fluorescence, sections were deparaffinized and rehydrated. Deparaffinization 
was carried out by incubating slides twice, 10 mins each, in xylenes. Using a decreasing ethanol gradient, tissue 
was rehydrated by the slides being sequentially moved through two incubations in 100% ethanol for 3 minutes 
each, one incubation in 95%, one incubation in 80%, and finally, rinsed in deionized water for at least five min-
utes. Before staining tissue sections, heat-induced epitope retrieval (HEIR) procedure was performed at 98 °C 
for 15–20 minutes to unmask the epitopes of proteins that were crosslinked during the paraffinization process. 
Specifically, sections that were stained for HLA-G (Santa Cruz, sc-21799, dilution 1:50), GFP (Aves, gfp-1020, 
dilution 1:500), CD3 (Biorbyt, orb323391, 1:100), CD4 (Invitrogen, MA1-81588, 1:100), and CD8 (Novus 
Biologicals, NB10064021, 1:100) were immersed into pre-heated citrate based antigen retrieval solution, pH 
6.0 (Vector Laboratories, H-3300), while the CD31 (Abcam, ab199012, 1 μg/ml) epitope was retrieved in 1 mM 
EDTA, pH 8.0, and the αSMA (Dako, M085101-2) epitope was retrieved in tris-based HEIR solution, pH 9.0 
(Vector Laboratories, H-3301). After HEIR was completed, slides were allowed to cool for 20 minutes at room 
temperature and then sections were washed twice for 5 minutes each in TBS plus 0.025% Triton X-100 with gentle 
agitation. The non-specific binding sites within the tissues were then blocked by incubating the slides with 10% 
normal serum, tissues stained for HLA-G were blocked with normal horse serum while all others were blocked 
with normal goat serum, with 1% BSA in TBS for 1 hour at RT. Blocking solution was drained off of the slides 
and sections were then incubated overnight at 4 °C with primary antibody diluted appropriately in TBS with 1% 
BSA. After incubation, sections were washed two times, 5 minutes each, with TBS plus 0.025% Triton X-100 with 
gentle agitation to remove primary antibody that was non-specifically bound. A suitable fluorophore-conjugated 
secondary antibody was diluted according to manufacturer suggestions in TBS plus 1% BSA and was then added 
to each tissue section and incubated for 1 hour at room temperature with gentle agitation. Finally, slides were 
washed three times with TBS, five minutes each. Nuclei within each section were stained when coverslips were 
mounted with ProLong Diamond Antifade Mountant with DAPI (Molecular Probes, P36971). As an additional 
measure of fibrosis, Masson trichrome staining was done by the CGIBD Histology core at the University of North 
Carolina at Chapel Hill and the expression of profibrotic proteins for each treatment group was evaluated through 
microscopy. Images from each slide were taken using an Olympus IX83 research inverted microscope with a 40X 
objective (Olympus, Tokyo, Japan) and processed using Olympus cellSans life science imaging software.
AAV8G9 Biodistribution following Stromal Injection. Serum was collected prior to the start and 
at the completion of these experiments and analyzed for neutralizing antibodies generated to the AAV capsid. 
Additionally, the liver, brain, kidney, heart, and draining lymph nodes were harvested for vector biodistribution 
assays using Q-PCR.
Neutralizing Antibody Assay. The presence of neutralizing antibodies in rabbit serum was assayed using 
a previously described method with a couple of slight modifications40. HEK293 cells were seeded in 24 well plates 
at 5 × 104 cells per well in 500 µl of complete DMEM (10% serum, 1% P/S). Cells were cultured for 24hrs at 37 °C 
and 5% CO2. Each rabbit’s pre- and post-injection serum was serially diluted, starting with twofold and going 
up to 1:256, in DPBS to a final volume of 12.5 µl. Serum dilutions were incubated with 3.84 × 108 viral genomes 
(7,680 genomes/cell) of AAV8G9-Luciferase for 2hr at 4 °C. The seeded HEK293 cells were then transduced with 
virus-serum mixtures for 48hrs under optimal culture conditions before transduction efficiency was measured 
by a luciferase assay.
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Luciferase Assay. Luciferase assay conducted to measure the transduction efficiency of AAV8G9 in the 
presence of rabbit serum. Promega Luciferase Assay System was performed as follows. A 1X lysis reagent was 
prepared by diluting 5x Promega Passive Lysis Buffer in ddH2O. Media was aspirated and cells lysed by adding 
250 µl of lysis reagent to each well of HEK293 cells and shaking the plate at room temp for 20 minutes. A mixture 
of 100 µl of lysed cells and 100 µl of Luciferase Assay Reagent was added to each well of a 96-well plate and using 
the Perkin Elmer Victor3 multilabel plate reader luminescence was measured as counts/second (CPS). Protein 
concentration was measured using a Nanodrop 2000c spectrophotometer and for each sample luciferase activity 
was normalized to the total protein concentration and reported as CPS/[P].
Statistical Analysis. Data generated from the experiments in this study were analyzed with GraphPad 
Prism, version 6.0, and the specific test used for analysis was the unpaired T test. Significance was set at p < 0.05 
for all comparisons in this study.
References
 1. Wang, H. M., Kaplan, H. J., Chan, W. C. & Johnson, M. The distribution and ontogeny of MHC antigens in murine ocular tissue. 
Invest Ophthalmol Vis Sci 28, 1383–1389 (1987).
 2. Streilein, J. W., Toews, G. B. & Bergstresser, P. R. Corneal allografts fail to express Ia antigens. Nature 282, 326–327 (1979).
 3. Lee, P., Wang, C. C. & Adamis, A. P. Ocular neovascularization: an epidemiologic review. Survey of ophthalmology 43, 245–269 
(1998).
 4. Amouzegar, A., Chauhan, S. K. & Dana, R. Alloimmunity and Tolerance in Corneal Transplantation. J Immunol 196, 3983–3991, 
https://doi.org/10.4049/jimmunol.1600251 (2016).
 5. Panda, A., Vanathi, M., Kumar, A., Dash, Y. & Priya, S. Corneal graft rejection. Survey of ophthalmology 52, 375–396, https://doi.
org/10.1016/j.survophthal.2007.04.008 (2007).
 6. Salganik, M., Hirsch, M. L. & Samulski, R. J. Adeno-associated Virus as a Mammalian DNA Vector. Microbiology spectrum 3, https://
doi.org/10.1128/microbiolspec.MDNA3-0052-2014 (2015).
 7. Hayamizu, T. F. et al. The mouse-human anatomy ontology mapping project. Database (Oxford) 2012, bar066, https://doi.
org/10.1093/database/bar066 (2012).
 8. Ge, H. Y. et al. Comparison of the antiangiogenic activity of modified RGDRGD-endostatin to endostatin delivered by gene transfer 
in vivo rabbit neovascularization model. Molecular vision 17, 1918–1928 (2011).
 9. Le Bouteiller, P. & Mallet, V. HLA-G and pregnancy. Reviews of reproduction 2, 7–13 (1997).
 10. Rebmann, V., da Silva Nardi, F., Wagner, B. & Horn, P. A. HLA-G as a tolerogenic molecule in transplantation and pregnancy. Journal 
of immunology research 2014, 297073, https://doi.org/10.1155/2014/297073 (2014).
 11. Ellis, S. A., Sargent, I. L., Redman, C. W. & McMichael, A. J. Evidence for a novel HLA antigen found on human extravillous 
trophoblast and a choriocarcinoma cell line. Immunology 59, 595–601 (1986).
 12. Carosella, E. D., Rouas-Freiss, N., Tronik-Le Roux, D., Moreau, P. & LeMaoult, J. HLA-G: An Immune Checkpoint Molecule. 
Advances in immunology 127, 33–144, https://doi.org/10.1016/bs.ai.2015.04.001 (2015).
 13. Ristich, V., Liang, S., Zhang, W., Wu, J. & Horuzsko, A. Tolerization of dendritic cells by HLA-G. European journal of immunology 
35, 1133–1142, https://doi.org/10.1002/eji.200425741 (2005).
 14. Carosella, E. D. The tolerogenic molecule HLA-G. Immunology letters 138, 22–24, https://doi.org/10.1016/j.imlet.2011.02.011 
(2011).
 15. Pankratz, S. et al. Human CD4+HLA-G+ regulatory T cells are potent suppressors of graft-versus-host disease in vivo. FASEB 
journal: official publication of the Federation of American Societies for Experimental Biology 28, 3435–3445, https://doi.org/10.1096/
fj.14-251074 (2014).
 16. Pankratz, S., Ruck, T., Meuth, S. G. & Wiendl, H. CD4(+)HLA-G(+) regulatory T cells: Molecular signature and pathophysiological 
relevance. Human immunology 77, 727–733, https://doi.org/10.1016/j.humimm.2016.01.016 (2016).
 17. Chiusolo, P. et al. The role of HLA–G 14-bp polymorphism in allo-HSCT after short-term course MTX for GvHD prophylaxis. Bone 
marrow transplantation 47, 120–124, https://doi.org/10.1038/bmt.2011.40 (2012).
 18. Liang, S., Baibakov, B. & Horuzsko, A. HLA-G inhibits the functions of murine dendritic cells via the PIR-B immune inhibitory 
receptor. European journal of immunology 32, 2418–2426, https://doi.org/10.1002/1521-4141(200209)32:9<2418::AID-
IMMU2418>3.0.CO;2-L (2002).
 19. McCarty, D. M. et al. Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the 
rate-limiting step to transduction in vivo. Gene therapy 10, 2112–2118, https://doi.org/10.1038/sj.gt.33021343302134 (2003).
 20. Wang, Z. et al. Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene 
therapy 10, 2105–2111, https://doi.org/10.1038/sj.gt.33021333302133 (2003).
 21. Vance, M. et al. AAV Gene Therapy for MPS1-associated Corneal Blindness. Scientific reports 6, 22131, https://doi.org/10.1038/
srep22131 (2016).
 22. Li, C. et al. Cellular immune response to cryptic epitopes during therapeutic gene transfer. Proc Natl Acad Sci USA 106, 
10770–10774, https://doi.org/10.1073/pnas.0902269106 (2009).
 23. McCarty, D. M., Monahan, P. E. & Samulski, R. J. Self-complementary recombinant adeno-associated virus (scAAV) vectors 
promote efficient transduction independently of DNA synthesis. Gene therapy 8, 1248–1254, https://doi.org/10.1038/sj.gt.3301514 
(2001).
 24. Fons, P. et al. Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor 
expressed by endothelial cells. Blood 108, 2608–2615, https://doi.org/10.1182/blood-2005-12-019919 (2006).
 25. Hirsch, M. L. et al. Oversized AAV transductifon is mediated via a DNA-PKcs-independent, Rad51C-dependent repair pathway. 
Molecular therapy: the journal of the American Society of Gene Therapy 21, 2205–2216, https://doi.org/10.1038/mt.2013.184 (2013).
 26. Wang, B., Li, J. & Xiao, X. Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular 
dystrophy in mdx mouse model. Proc Natl Acad Sci USA 97, 13714–13719, https://doi.org/10.1073/pnas.240335297 (2000).
 27. Sethupathy, P. & Collins, F. S. MicroRNA target site polymorphisms and human disease. Trends in genetics: TIG 24, 489–497, https://
doi.org/10.1016/j.tig.2008.07.004 (2008).
 28. Vasudevan, S., Tong, Y. & Steitz, J. A. Switching from repression to activation: microRNAs can up-regulate translation. Science 318, 
1931–1934, https://doi.org/10.1126/science.1149460 (2007).
 29. Hippert, C. et al. Corneal transduction by intra-stromal injection of AAV vectors in vivo in the mouse and ex vivo in human 
explants. PloS one 7, e35318, https://doi.org/10.1371/journal.pone.0035318 (2012).
 30. Zhu, X. M. et al. Overexpression of miR-152 leads to reduced expression of human leukocyte antigen-G and increased natural killer 
cell mediated cytolysis in JEG-3 cells. American journal of obstetrics and gynecology 202(592), e591–597, https://doi.org/10.1016/j.
ajog.2010.03.002 (2010).
 31. Wang, X. et al. Evidence that miR-133a causes recurrent spontaneous abortion by reducing HLA-G expression. Reproductive 
biomedicine online 25, 415–424, https://doi.org/10.1016/j.rbmo.2012.06.022 (2012).
www.nature.com/scientificreports/
1 1Scientific REPORTS |  (2017) 7:17840  | DOI:10.1038/s41598-017-18002-9
 32. Tornoe, J., Kusk, P., Johansen, T. E. & Jensen, P. R. Generation of a synthetic mammalian promoter library by modification of 
sequences spacing transcription factor binding sites. Gene 297, 21–32 (2002).
 33. Mohan, R. R. et al. Apoptosis, necrosis, proliferation, and myofibroblast generation in the stroma following LASIK and PRK. 
Experimental eye research 76, 71–87 (2003).
 34. Amiot, L. et al. Expression of HLA-G by mast cells is associated with hepatitis C virus-induced liver fibrosis. Journal of hepatology 
60, 245–252, https://doi.org/10.1016/j.jhep.2013.09.006 (2014).
 35. Wang, Y., Yin, H., Chen, P., Xie, L. & Wang, Y. Inhibitory effect of canstatin in alkali burn-induced corneal neovascularization. 
Ophthalmic research 46, 66–72, https://doi.org/10.1159/000322804 (2011).
 36. Ye, J., Yao, K. & Kim, J. C. Mesenchymal stem cell transplantation in a rabbit corneal alkali burn model: engraftment and involvement 
in wound healing. Eye 20, 482–490, https://doi.org/10.1038/sj.eye.6701913 (2006).
 37. Burgess, A. et al. Loss of human Greatwall results in G2 arrest and multiple mitotic defects due to deregulation of the cyclin B-Cdc2/
PP2A balance. Proc Natl Acad Sci USA 107, 12564–12569, https://doi.org/10.1073/pnas.0914191107 (2010).
 38. McCloy, R. A. et al. Partial inhibition of Cdk1 in G 2 phase overrides the SAC and decouples mitotic events. Cell cycle (Georgetown, 
Tex.) 13, 1400–1412, https://doi.org/10.4161/cc.28401 (2014).
 39. Mercadal, C. M., Bouley, D. M., DeStephano, D. & Rouse, B. T. Herpetic stromal keratitis in the reconstituted scid mouse model. 
Journal of virology 67, 3404–3408 (1993).
 40. Li, C. et al. Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia. 
Gene therapy. https://doi.org/10.1038/gt.2011.90 (2011).
Acknowledgements
The authors thank Dr. Freya Mowat for use of her scanning laser ophthalmoscope, Dr. Thomas McCown for 
aid with brain dissections, Dr. Jacquelyn Bower for reviewing this manuscript, UNC CGIBD Histology Core 
facility and histology technician, Carolyn Suitt, for the work done to provide slides for our research, and the 
staff of the UNC Vector Core for production of viral vectors used for in vivo experiments. A portion of the 
imaging was done using the Neuroscience Center Microscopy Core Facility equipment, which is supported 
by funding from the NIH-NINDS Neuroscience Center Support Grant P30 NS045892 and the NIH-NICHD 
Intellectual and Developmental Disabilities Research Center Support Grant U54HD079124. NCTraCS (MH), 
NIH RO1AI072176-06A1 and RO1AR064369-01A1, and NIH Grant P30 DK 034987.
Author Contributions
M.H., B.G., and R.D. conceived and designed the studies; L.C., S.S., J.S., N.B., and J.W. performed experiments; 
M.H., B.G., L.C., and S.S. collected and analyzed data; M.H., L.C., B.G. wrote the manuscript; J.S. provided 
technical and managerial support.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-017-18002-9.
Competing Interests: MH and BG have submitted a provisional patent regarding optHLA-G as a therapy for 
ocular diseases which has been licensed to Tamid Bio. MH is a consultant to Tamid Bio and has also received 
royalties from Asklepios BioPharmaceutical related to patent #9447433.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2017
